Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | SCN4A | P35499 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3835050 | 0.78 | ELANE (0.43) | ELANESCN4AHTR2CHTR2BCYP1A2 | |
| SCHEMBL21853238 | 0.77 | ELANE (0.42) | ELANECHRNB2CHRNA4SCN4AHTR2C | |
| SCHEMBL21853251 | 0.77 | ELANE (0.42) | ELANECHRNB2CHRNA4SCN4AHTR2C | |
| SCHEMBL16197773 | 0.72 | HTT (0.46) | ELANESCN4AHTR2CHTR2B | |
| SCHEMBL3060268 | 0.72 | HTT (0.46) | ELANESCN4AHTR2CHTR2B | |
| SCHEMBL30181464 | 0.71 | CHRNA3 (0.64) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL29007986 | 0.71 | CHRNA3 (0.64) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL29007987 | 0.71 | CHRNA3 (0.64) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL23356900 | 0.71 | DPP4 (0.49) | ELANESCN4AHTR2CHTR2BALDH1A1 | |
| SCHEMBL2016284 | 0.71 | DPP4 (0.49) | ELANESCN4AHTR2CHTR2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153850-A1 | Adamantyl Derivates as P2x7 Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153850-A1 | Adamantyl Derivates as P2x7 Receptor Antagonists | ADORA1, P2RX1, P2RY1 | CHRNB4 487/4885CHRNA3 217/4885ELANE 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.